The GlaxoSmithKline (GSK) Translational Molecular Imaging Hub, a pioneering public-private partnership developed by EATRIS and GSK, will soon be concluding. Since its inception in 2018, this collaborative imaging Hub has united scientific and clinical experts to advance innovative imaging methods for inflammatory diseases, achieving progress in translating research findings into clinical applications.
The Hub has not only enhanced imaging capabilities for GSK’s clinical trials but has also provided opportunities for academic researchers with access to GSK’s expertise, resources and infrastructure. Over 25 collaborative agreements were executed and several more scientific concepts, proposals and knowledge were exchanged. These efforts bridged academia and industry to overcome complex challenges in developing and deploying new imaging technologies.
Prof. Dr. J. van der Laken (Professor of Imaging at the Amsterdam UMC Department of Rheumatology) reflected on the Hub: “For several years, the EATRIS-GSK Hub has been an excellent and very constructive example of efficient collaboration between public and private partners. Working under a master agreement has greatly facilitated individual and joint translational and clinical projects. The focus of the Hub was molecular imaging of immune targets. Discussions between public and private collaborators were complementary and highly valuable. Several successful translational and clinical projects were generated and conducted. The generated outcome has boosted novel research and collaborations. EATRIS has greatly supported the Hub in several aspects including planning and construction of meetings, legal support, communication, and dissemination. The large network of EATRIS was also beneficial for the Hub.”
EATRIS’s role in promoting collaboration across sectors was highlighted in the 2023 ‘ESFRI RIs Industry Cooperation’ report, with a specific mention of the GSK Hub. Further, the European Commission selected the EATRIS-GSK Imaging Hub as an example of the best practice of public-private collaboration to feature on the EU Knowledge Valorisation Platform. These acknowledgements stand as a testament to the collective dedication of all involved with the Hub to translating scientific knowledge into innovative solutions for the benefit of patients.
As we celebrate the successes of the EATRIS-GSK Imaging Hub, we thank everyone involved in this journey for their commitment and contributions, and we remain excited about continuing to foster impactful collaborations in translational research.
Find out more:
- EATRIS highlighted in ESFRI Industry Cooperation Report
- EATRIS and GlaxoSmithKline to Extend Translational Molecular Imaging Hub Collaboration with Maturing Project Portfolio
- Innovation Hubs: EATRIS and GlaxoSmithKline Extend Collaboration for Three Additional Years
- European Commission Selects EATRIS Best Practices for EU Knowledge Valorisation Platform
- The EATRIS public-private innovation hub | EC Research and Innovation
